The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers

Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemieux, J., Clemons, M., Provencher, L., Dent, S., Latreille, J., Mackey, J., Pritchard, K.I., Rayson, D., Verma, Sh., Verma, Su., Wang, B., Chia, S.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Practice Guidelines Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768514/
https://www.ncbi.nlm.nih.gov/pubmed/19862361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768514/
https://www.ncbi.nlm.nih.gov/pubmed/19862361

Ejemplares similares